founded in 1989, cryo-cell is the oldest cord blood bank and was the first cord blood bank to separate and store stem cells in 1992. today, the company has over 270,000 clients worldwide. since inception, 100% of our clients’ specimens have been successfully viable upon thaw. our services include umbilical cord blood, cord tissue and menstrual stem cell banking. cryo-cell operates its own state-of-the-art processing, testing and cryopreservation operation. we are in complete control of every step, ensuring the highest quality available today.
Company profile
Ticker
CCEL
Exchange
Website
CEO
Mark L. Portnoy / David I. Portnoy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
223023093
CCEL stock data
Latest filings (excl ownership)
8-K
Cryo-cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value
26 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
12 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
12 Oct 23
ARS
2022 FY
Annual report to shareholders
15 Sep 23
DEF 14A
Definitive proxy
14 Sep 23
8-K
Other Events
25 Aug 23
10-Q
2023 Q2
Quarterly report
14 Jul 23
10-Q
2023 Q1
Quarterly report
21 Apr 23
NT 10-Q
Notice of late quarterly filing
14 Apr 23
Latest ownership filings
Financial summary
Quarter (USD) | Aug 23 | May 23 | Feb 23 | Nov 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Nov 22 | Nov 21 | Nov 20 | Nov 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 584.00 k | 584.00 k | 584.00 k | 584.00 k | 584.00 k | 584.00 k |
Cash burn (monthly) | 180.00 k | 195.06 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 1.25 mm | 1.35 mm | n/a | n/a | n/a | n/a |
Cash remaining | -665.81 k | -770.36 k | n/a | n/a | n/a | n/a |
Runway (months of cash) | -3.7 | -3.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q2 2023
12.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 2.55 bn |
Total shares | 1.02 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hamilton Lane Advisors | 409.73 k | $2.49 mm |
Iszo Capital | 195.03 k | $0.00 |
SFI Advisors | 165.30 k | $1.01 bn |
Massmutual Trust Co FSB | 124.14 k | $754.82 mm |
Vanguard | 73.79 k | $448.68 mm |
Cerity Partners | 19.56 k | $118.96 mm |
Geode Capital Management | 19.08 k | $116.02 mm |
BLK Blackrock | 13.96 k | $84.89 mm |
Advisor | 2.50 k | $15.20 mm |
MS Morgan Stanley | 400.00 | $2.43 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Dec 23 | Jill M Taymans | Stock Option Common Stock | Grant | Acquire A | No | No | 5.88 | 10,000 | 58.80 k | 10,000 |
22 Dec 23 | Oleg Mikulinsky | Stock Option Common Stock | Grant | Acquire A | No | No | 5.88 | 10,000 | 58.80 k | 10,000 |
22 Dec 23 | Portnoy David | Stock Option Common Stock | Grant | Acquire A | No | No | 6.47 | 50,000 | 323.50 k | 50,000 |
22 Dec 23 | Portnoy Mark L. | Stock Option Common Stock | Grant | Acquire A | No | No | 6.47 | 25,000 | 161.75 k | 25,000 |
10 Oct 23 | Berger Harold D. | Stock Option Common Stock | Grant | Acquire A | No | No | 4.9 | 5,300 | 25.97 k | 5,300 |